Asset & partnering strategy

Positioning your asset where it can win

We start from your clinical plan and evidence, then build a partner-ready thesis and BD plan. Together we define which pharma/biopharma targets matter most, how your asset stacks up in their portfolio and TA focus, and what they need to see to move from intro to meeting, diligence, and term sheet.

From strategy to a partner-ready package

We prioritise potential partners by therapeutic area, mechanism, stage, and deal history, then use warm BD&L access to open the right doors. In parallel, we assemble the core package—indication strategy, TPP, clinical and CMC briefs, IP/FTO note, and early HEOR outline—so each conversation is grounded in evidence and aligned with payer and regulator expectations.

Turning strategy into concrete options

Based on this groundwork, we frame realistic deal and partnering scenarios: global vs regional, co-dev vs straight licensing, options vs full rights. We model high-level economics and governance so you can see what “good” looks like before you step into negotiations, and we map outreach around key calendars (data drops, congresses, regulatory milestones) to maximise traction.

Key areas of asset & partnering strategy

• TA & partner prioritisation – Ranking pharma/biopharma targets by TA, mechanism, stage, and deal track record.

• Partnering thesis & calendars – Defining who to approach, with which story, and around which scientific and industry milestones.

• Partner-ready materials – Non-conf and confidential decks, TPP, clinical & CMC briefs, IP/FTO note, HEOR outline, and diligence Q&A log.

• Economics & scenarios – High-level deal model (upfronts, milestones, royalties) and draft term sheet options.

• Governance & BD blueprint – Alliance governance strawman and a simple BD operating model with stages, ownership, and decision gates.

“Strong deals start long before term sheets—with the right targets, the right story, and a disciplined plan to reach them.”

With a defined asset and partnering strategy, your business development work becomes a disciplined engine: you know which partners to prioritise, which materials to bring, and which deal shapes you are optimising for.